Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease
Identifieur interne :
003587 ( PascalFrancis/Corpus );
précédent :
003586;
suivant :
003588
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease
Auteurs : L. V. Metman ;
V. H. Sethy ;
J. R. Roberts ;
D. Bravi ;
J. I. Hoff ;
M. M. Mouradian ;
T. N. ChaseSource :
-
Movement disorders [ 0885-3185 ] ; 1994.
RBID : Pascal:94-0649262
Descripteurs français
English descriptors
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 9 |
|---|
| A06 | | | | @2 5 |
|---|
| A08 | 01 | 1 | ENG | @1 Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease |
|---|
| A11 | 01 | 1 | | @1 METMAN (L. V.) |
|---|
| A11 | 02 | 1 | | @1 SETHY (V. H.) |
|---|
| A11 | 03 | 1 | | @1 ROBERTS (J. R.) |
|---|
| A11 | 04 | 1 | | @1 BRAVI (D.) |
|---|
| A11 | 05 | 1 | | @1 HOFF (J. I.) |
|---|
| A11 | 06 | 1 | | @1 MOURADIAN (M. M.) |
|---|
| A11 | 07 | 1 | | @1 CHASE (T. N.) |
|---|
| A14 | 01 | | | @1 NIH, national inst. neurological disorders stroke @2 Bethesda MD 20892 @3 USA |
|---|
| A20 | | | | @1 577-581 |
|---|
| A21 | | | | @1 1994 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000041303820110 |
|---|
| A44 | | | | @0 0000 |
|---|
| A45 | | | | @0 17 ref. |
|---|
| A47 | 01 | 1 | | @0 94-0649262 |
|---|
| A60 | | | | @1 P |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C02 | 01 | X | | @0 002B02B06 |
|---|
| C03 | 01 | X | FRE | @0 Parkinson maladie @2 NM @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Parkinson disease @2 NM @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Parkinson enfermedad @2 NM @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Préclamol @2 NK @2 FR @5 04 |
|---|
| C03 | 03 | X | FRE | @0 Agoniste partiel @5 05 |
|---|
| C03 | 03 | X | ENG | @0 Partial agonist @5 05 |
|---|
| C03 | 03 | X | SPA | @0 Agonista parcial @5 05 |
|---|
| C03 | 04 | X | FRE | @0 Dopamine @2 NK @2 FR @5 06 |
|---|
| C03 | 04 | X | ENG | @0 Dopamine @2 NK @2 FR @5 06 |
|---|
| C03 | 04 | X | SPA | @0 Dopamina @2 NK @2 FR @5 06 |
|---|
| C03 | 05 | X | FRE | @0 Antiparkinsonien @5 16 |
|---|
| C03 | 05 | X | ENG | @0 Antiparkinson agent @5 16 |
|---|
| C03 | 05 | X | SPA | @0 Antiparkinsoniano @5 16 |
|---|
| C03 | 06 | X | FRE | @0 Traitement @5 17 |
|---|
| C03 | 06 | X | ENG | @0 Treatment @5 17 |
|---|
| C03 | 06 | X | GER | @0 Aufbereiten @5 17 |
|---|
| C03 | 06 | X | SPA | @0 Tratamiento @5 17 |
|---|
| C03 | 07 | X | FRE | @0 Homme @5 20 |
|---|
| C03 | 07 | X | ENG | @0 Human @5 20 |
|---|
| C03 | 07 | X | SPA | @0 Hombre @5 20 |
|---|
| C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
|---|
| C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
|---|
| C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
|---|
| C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
|---|
| C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
|---|
| C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
|---|
| C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
|---|
| C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
|---|
| C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
|---|
| C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
|---|
| C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
|---|
| C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
|---|
| C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
|---|
| C07 | 06 | X | FRE | @0 Chimiothérapie @5 45 |
|---|
| C07 | 06 | X | ENG | @0 Chemotherapy @5 45 |
|---|
| C07 | 06 | X | SPA | @0 Quimioterapia @5 45 |
|---|
| N21 | | | | @1 313 |
|---|
|
|---|
Format Inist (serveur)
| NO : | PASCAL 94-0649262 INIST |
|---|
| ET : | Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease |
|---|
| AU : | METMAN (L. V.); SETHY (V. H.); ROBERTS (J. R.); BRAVI (D.); HOFF (J. I.); MOURADIAN (M. M.); CHASE (T. N.) |
|---|
| AF : | NIH, national inst. neurological disorders stroke/Bethesda MD 20892/Etats-Unis |
|---|
| DT : | Publication en série; Niveau analytique |
|---|
| SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1994; Vol. 9; No. 5; Pp. 577-581; Bibl. 17 ref. |
|---|
| LA : | Anglais |
|---|
| CC : | 002B02B06 |
|---|
| FD : | Parkinson maladie; Préclamol; Agoniste partiel; Dopamine; Antiparkinsonien; Traitement; Homme |
|---|
| FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Chimiothérapie |
|---|
| ED : | Parkinson disease; Partial agonist; Dopamine; Antiparkinson agent; Treatment; Human |
|---|
| EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Chemotherapy |
|---|
| GD : | Aufbereiten |
|---|
| SD : | Parkinson enfermedad; Agonista parcial; Dopamina; Antiparkinsoniano; Tratamiento; Hombre |
|---|
| LO : | INIST-20953.354000041303820110 |
|---|
| ID : | 94-0649262 |
|---|
Links to Exploration step
Pascal:94-0649262
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease</title>
<author><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
<affiliation><inist:fA14 i1="01"><s1>NIH, national inst. neurological disorders stroke</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
</inist:fA14><author><name sortKey="Sethy, V H" sort="Sethy, V H" uniqKey="Sethy V" first="V. H." last="Sethy">V. H. Sethy</name>
</author><author><name sortKey="Roberts, J R" sort="Roberts, J R" uniqKey="Roberts J" first="J. R." last="Roberts">J. R. Roberts</name>
</author><author><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D." last="Bravi">D. Bravi</name>
</author><author><name sortKey="Hoff, J I" sort="Hoff, J I" uniqKey="Hoff J" first="J. I." last="Hoff">J. I. Hoff</name>
</author><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
</author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
</author><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">94-0649262</idno>
<date when="1994">1994</date>
<idno type="stanalyst">PASCAL 94-0649262 INIST</idno>
<idno type="RBID">Pascal:94-0649262</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003587</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease</title>
<author><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
<affiliation><inist:fA14 i1="01"><s1>NIH, national inst. neurological disorders stroke</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
</inist:fA14><author><name sortKey="Sethy, V H" sort="Sethy, V H" uniqKey="Sethy V" first="V. H." last="Sethy">V. H. Sethy</name>
</author><author><name sortKey="Roberts, J R" sort="Roberts, J R" uniqKey="Roberts J" first="J. R." last="Roberts">J. R. Roberts</name>
</author><author><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D." last="Bravi">D. Bravi</name>
</author><author><name sortKey="Hoff, J I" sort="Hoff, J I" uniqKey="Hoff J" first="J. I." last="Hoff">J. I. Hoff</name>
</author><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
</author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
</author><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1994">1994</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Dopamine</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Partial agonist</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Préclamol</term>
<term>Agoniste partiel</term>
<term>Dopamine</term>
<term>Antiparkinsonien</term>
<term>Traitement</term>
<term>Homme</term>
</keywords><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA08 i1="01" i2="1" l="ENG"><s1>Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease</s1>
</fA08><fA11 i1="01" i2="1"><s1>METMAN (L. V.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>SETHY (V. H.)</s1>
</fA11><fA11 i1="03" i2="1"><s1>ROBERTS (J. R.)</s1>
</fA11><fA11 i1="04" i2="1"><s1>BRAVI (D.)</s1>
</fA11><fA11 i1="05" i2="1"><s1>HOFF (J. I.)</s1>
</fA11><fA11 i1="06" i2="1"><s1>MOURADIAN (M. M.)</s1>
</fA11><fA11 i1="07" i2="1"><s1>CHASE (T. N.)</s1>
</fA11><fA14 i1="01"><s1>NIH, national inst. neurological disorders stroke</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
</fA14><fA20><s1>577-581</s1>
</fA20><fA21><s1>1994</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000041303820110</s5>
</fA43><fA44><s0>0000</s0>
</fA44><fA45><s0>17 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>94-0649262</s0>
</fA47><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Préclamol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Agoniste partiel</s0>
<s5>05</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Partial agonist</s0>
<s5>05</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Agonista parcial</s0>
<s5>05</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>16</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>16</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>16</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03><fC03 i1="06" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07><fC07 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>45</s5>
</fC07><fC07 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>45</s5>
</fC07><fC07 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>45</s5>
</fC07><fN21><s1>313</s1>
</fN21><server><NO>PASCAL 94-0649262 INIST</NO>
<ET>Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease</ET>
<AU>METMAN (L. V.); SETHY (V. H.); ROBERTS (J. R.); BRAVI (D.); HOFF (J. I.); MOURADIAN (M. M.); CHASE (T. N.)</AU>
<AF>NIH, national inst. neurological disorders stroke/Bethesda MD 20892/Etats-Unis</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1994; Vol. 9; No. 5; Pp. 577-581; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Préclamol; Agoniste partiel; Dopamine; Antiparkinsonien; Traitement; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Chimiothérapie</FG>
<ED>Parkinson disease; Partial agonist; Dopamine; Antiparkinson agent; Treatment; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Chemotherapy</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Agonista parcial; Dopamina; Antiparkinsoniano; Tratamiento; Hombre</SD>
<LO>INIST-20953.354000041303820110</LO>
<ID>94-0649262</ID>
</server>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003587 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003587 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:94-0649262
|texte= Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
